论文部分内容阅读
目的:探讨冠心病患者低密度脂蛋白与血小板功能活化产物GMP-140的关系。方法:应用酶联免疫分析法对120例研究对象进行了血浆LDL、GMP-140水平的测定,其中包括急性冠脉综合征组40例,稳定性心绞痛组40例,并与40例正常健康人作比较。结果:ACS患者血浆LDL和GMP-140水平均非常显著的高于正常人组(P<0.01),ACS组又高于SAP组(P<0.05),且血浆LDL与GMP-140水平呈正相关。结论:检测CHD患者血浆LDL和GMP-140水平的变化对CHD的发生和发展以及疗效和预后观察均具有重要的临床意义。
Objective: To investigate the relationship between low density lipoprotein (LDL) and functional platelet activation (GMP-140) in patients with coronary heart disease. Methods: Serum LDL and GMP-140 levels were measured in 120 subjects by enzyme-linked immunosorbent assay (ELISA), including 40 cases of acute coronary syndrome and 40 cases of stable angina pectoris. Forty patients with normal healthy subjects compared to. Results: The levels of plasma LDL and GMP-140 in patients with ACS were significantly higher than those in normal controls (P <0.01). ACS patients were significantly higher than those in SAP patients (P <0.05). Plasma LDL was positively correlated with GMP-140. Conclusion: The changes of plasma LDL and GMP-140 levels in patients with CHD have important clinical significance for the occurrence and development of CHD and the curative effect and prognosis.